CLASS II Device recall · Reported 24 Oct 2018 · FDA Enforcement Report

Mindray BeneVision Distributed Monitoring System (DMS) recalled

Mindray DS USA is recalling Mindray BeneVision Distributed Monitoring System (DMS), distributed in 9 states. The recall was initiated on 30 Aug 2018 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesThis potential issue affects BeneVision DMS with software version 03.01.00 to 03.03.00
Quantity recalled5

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-0170-2019
FDA event ID
81084
Recalling firm
Mindray DS USA, Mahwah, NJ
Classification
Class II
Status
Terminated
Recall initiated
30 Aug 2018
FDA classified
17 Oct 2018
Reported
24 Oct 2018
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons
Device type
Patient Monitors

Timeline

30 Aug 2018Recall initiated by company
17 Oct 2018Classified by FDA+48 days
24 Oct 2018Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

The firm has identified performance anomalies with the device caused when more than 64 TD60 telemetry transmitters have been connected to a central station. The anomaly causes some ECG waveforms to appear as a flat line at the centralized viewing station and will manifest if more than 64 TD60 transmitters have been connected to a given central station server. Each central station supports only 32 transmitters at a time. For the issue to manifest, the BeneVision DMS needs to be configured to use flexible device assignment, have more than 64 TD60 transmitters, and the workflow must allow 64 TD60s to move around between multiple central stations in the same care area.

Product as listed by the FDA

Mindray BeneVision Distributed Monitoring System (DMS), Part No. 115-034413-00

Where it was distributed

Distributed to accounts in CA, CO, FL, MA, NY, PA, PR, TX, and WV.

CaliforniaColoradoFloridaMassachusettsNew YorkPennsylvaniaPuerto RicoTexasWest Virginia

Questions about this recall

Is Mindray BeneVision Distributed Monitoring System (DMS) recalled?

Yes. Mindray DS USA recalled Mindray BeneVision Distributed Monitoring System (DMS) on 30 Aug 2018. The recall is Class II and its status is Terminated. Recall number Z-0170-2019.

Why was it recalled?

The firm has identified performance anomalies with the device caused when more than 64 TD60 telemetry transmitters have been connected to a central station. The anomaly causes some ECG waveforms to appear as a flat line at the centralized viewing station and will manifest if more than 64 TD60 transmitters have been connected to a given central station server. Each central station supports only 32 transmitters at a time. For the issue to manifest, the BeneVision DMS needs to be configured to use flexible device assignment, have more than 64 TD60 transmitters, and the workflow must allow 64 TD60s to move around between multiple central stations in the same care area.

Which lots are affected?

This potential issue affects BeneVision DMS with software version 03.01.00 to 03.03.00

Where was it sold?

Distributed to accounts in CA, CO, FL, MA, NY, PA, PR, TX, and WV.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Mindray DS USA

All 39

Other Patient Monitors recalls

All 1,013